Assessment of lymphoid cell immunophenotype in laryngeal carcinoma (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Assessment of lymphoid cell immunophenotype in laryngeal carcinoma (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 14:A883 1995. Unique Identifier : AIDSLINE ICDB/95614035
Kulczynski B; Grezegorz D; Kruk-Zagajewski A; Adryanczyk R; Dept. of Otolaryngology, Karol Marcinkowski University of Medical; Sciences 60 355 Poznan, Poland

Abstract: Determination of cell immunophenotype of cancer patients was found useful in the assessment of immune competence. We attempted to examine an immunophenotype of laryngeal carcinoma patients at the time of surgery. We used both, patients blood lymphocytes (PBL) and tumor infiltrating lymphocytes (TIL) isolated from resected cancer tissue. TIL were isolated by mechanical and/or enzymatic disaggregation of tissue followed by centrifugation on density gradient. PBL were isolated by standard techniques. Both blood cells and TIL were allowed to react with monoclonal antibodies vs lymphocyte/monocyte differentiation antigens and analyzed by flow cytometry. It has been found that in the blood of about half of patients percent of natural killer (NK) cells (CD56+, CD16+) was increased. It was accompanied by reverse CD4:CD8 T cell ratio. When TIL were examined cell percent values did not correspond to those found in the blood of the same patient. In general, CD4:CD8 ratio was low but oscillated around 1.0. NK cell values tended to be lower while B cells (CD19+) were higher than in the blood. An interesting feature of TIL was clear-cut subset of CD3+DR+ cells. These data indicate that larynx cancer patients show alterations in lymphoid cell phenotype at time of surgery.

Keywords: Antibodies, Monoclonal/IMMUNOLOGY Antigens, Differentiation/IMMUNOLOGY CD4-CD8 Ratio Flow Cytometry Human Immunophenotyping Laryngeal Neoplasms/*IMMUNOLOGY Lymphocytes/*IMMUNOLOGY ABSTRACT
951230
M95C3215

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .